I am excited by the prospect of continuing to build and enhance Bioclinica’s technology and service offering and working to help our clients improve clinical trial outcomes in the years ahead.
Doylestown, Pa. (PRWEB) November 29, 2017
Bioclinica®, a world-leading provider of specialty clinical trial services, has appointed David Herron as the company’s next Chief Executive Officer, effective January 2, 2018. This follows the planned retirement of current Chief Executive Officer, John Hubbard, PhD, who will remain as a non-Executive Director on the Bioclinica Board.
With more than 10 years’ of experience at Bioclinica, David Herron has led the company’s Medical Imaging business to great success. During his tenure, he integrated three of the industry’s leading medical imaging companies (Bioclinica, Corelab Partners, and Synarc) into one comprehensive service provider. Focusing on both operational excellence and process efficiency, Herron has grown the business into the world’s largest independent supplier of medical imaging services for clinical trials.
Recently Herron assumed the additional responsibility of leading Bioclinica’s technology-focused eHealth segment, immediately creating new synergies that leverage Bioclinica’s multi-faceted capabilities. With appointment to CEO, his oversight will extend to Bioclinica’s network of investigator sites and patient recruitment businesses for a unified clinical trial service offering unmatched in the industry.
Herron has more than 25 years’ experience in healthcare technology, medical services and consulting, having worked at Ernst & Young, Caremark/CVS, HealthNet, and Webify Solutions/IBM.
Dr. John Hubbard, current Chief Executive Officer of Bioclinica said, “It has been a privilege to serve as Chief Executive of Bioclinica for the past three years, however, now is the right time for me to take on a new role and welcome David to the Board. This key transition has been core in our succession planning process. I’ve seen David successfully assume greater responsibility in the organization where he’s been integral in Bioclinica’s transformation over the last four years. I have every confidence in his ability to lead Bioclinica in the next phase of growth.”
Herron commented, “I would like to thank John for his significant contribution as Chief Executive of Bioclinica for the last three years and I look forward to continue working with him in his new capacity as non-Executive Director. I am excited by the prospect of continuing to build and enhance Bioclinica’s technology and service offering and working to help our clients improve clinical trial outcomes in the years ahead.”
Bioclinica is a global life sciences solution provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. Successful clinical trials require the ability to see key details and uncover hidden insights, and Bioclinica’s hundreds of experienced scientific, medical, and domain experts bring unmatched insight across the development lifecycle, from the initial protocol to post-approval. The company’s cloud-based offerings include medical imaging; cardiac safety; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site payments and forecasting; pharmacovigilance; trial management; and risk-based monitoring solutions. A true multifaceted partner to trial sponsors and Contract Research Organizations (CROs), Bioclinica offers an integrated App xChange partner ecosystem, a global network of research sites, patient recruitment services, and post-approval research expertise to provide committed, detail-focused service through all stages of drug development. The company’s thousands of employees serve more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 biopharmaceutical companies and leading CROs – through a network of offices in the U.S., Europe, and Asia.